This study is a multicenter, prospective, open-label, endpoint-blind, randomized controlled study.Patients receiving surgical treatment for SICH were divided into groups using the random machine method. In addition to conventional treatment for spontaneous intracerebral hemorrhage, patients in the group of early initiation of antiplatelet therapy were given conventional dose of aspirin (100mg, qd) antiplatelet therapy starting from the 3rd day after surgery.An independent group of investigators evaluated cardiac, cerebral and peripheral vascular events and bleeding events at four different time points.To evaluate the benefits and safety of early postoperative initiation of antiplatelet therapy in patients with spontaneous intracerebral hemorrhage.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
269
using antiplatelet agents in 3 days after surgery
Capital Medical University Affiliated Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
rate of intracranial hemorrhage
Time frame: 7 days after surgery
rate of intracranial hemorrhage
Time frame: 14 days after surgery
rate of intracranial hemorrhage
Time frame: 30 days after surgery
rate of intracranial hemorrhage
Time frame: 90 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time frame: 7 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time frame: 14 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time frame: 30 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time frame: 90 days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.